Medicare Shared Savings Program
Accountable Care Organization (ACO)
Measure Deep Dive Series

Preventive Care and Screening (Prev-13)
Measure 42 – Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

• Objective(s):
  – Understand acceptable documentation required to successfully satisfy the multiple questions for the Statin Therapy measure
  – Understand the age parameters for each Risk Category
  – Understand the measurement period and lookback time for each Risk category
  – Understand measure exclusion
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

**Measure Description:** Percentage of the following beneficiaries – all considered at high risk of cardiovascular events, who were prescribed or were on Statin therapy during the measurement period:

- Adults 21 years and older who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR
- Adults 21 years and older with a fasting or direct low-density lipoprotein cholesterol (LDL-C) level $\geq 190$ mg/dL; OR
- Adults 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

**Age Parameters:**
- Risk Category 1: Age 21 years and older
- Risk Category 2: Age 21 years and older
- Risk Category 3: 40-75 years of age
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

Determine if the patient is qualified for the measure. The measure qualification answer is “Yes” unless prior approval is received to select:

- **No – Other CMS Approved Reason**
  - This answer is only acceptable with approval from the Centers for Medicare & Medicaid Services (CMS)
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

**Risk Category 1**  (For patients 21 years and older)

1. Does the patient have a diagnosis of ASCVD (active or history of) at any time up through the last day of the measurement period?
   - **Yes**
     - Patient has a diagnosis of ASCVD (active or history of) documented in the patient's medical record (Skip to Statin Therapy question)
   - **No - Diagnosis**
     - Unable to confirm the diagnosis of ASCVD (active or history of) documented in the patient's medical record (If selected - Continue to Risk 2 Category)

**Note:** Clinical Atherosclerotic Cardiovascular Disease (ASCVD) is defined as:
- Acute Coronary Syndromes,
- History of Myocardial Infarction,
- Stable or Unstable Angina,
- Coronary or other Arterial Revascularization,
- Stroke or Trans Ischemic Attack (TIA),
- Peripheral Artery Disease (PAD) of atherosclerotic origin
Risk Category 2 (For patients 21 years an older)

2. Has the patient ever had a fasting or direct LDL-C ≥ 190 mg/dL?
   • Yes
     − Patient has ever had a fasting or direct LDL-C ≥ 190 mg/dL documented (If selected - Skip to Statin Therapy Question)
   • No - Diagnosis
     − Patient has never had a fasting or direct LDL-C ≥190 mg/dL documented (If selected - Continue to Risk 3 Category)
Risk Category 3  (For patients aged 40-75)

3. Is the patient’s age 40-75 and has a diagnosis of Type I or Type II diabetes?
   • Yes
     – Patient is aged 40-75 and has a diagnosis of Type 1 or Type 2 Diabetes
   • No - Diagnosis
     – Patient is not aged 40-75 or does not have a diagnosis of Type 1 or Type 2 Diabetes
       (If selected – Stop Abstraction for this measure)
4. Did the patient have an LDL-C level of 70-189 mg/dL during the measurement period (2017) or two years prior to the measurement period (2015-2016)?

- Yes
  - Patient has an LDL-C 70-189 mg/dL documented (If selected – Skip to Statin Therapy Question)

- No
  - Patient does not have an LDL-C 70-189 mg/dL documented (If selected – Stop Abstraction for this measure)

- No – Other CMS Approved Reason (QR only)
  - This answer is only acceptable with approval from CMS

Note: The LDL-C result recorded should be the highest fasting or direct laboratory test result in the measurement period or during the two years prior to the measurement period.
5. Does the patient have an active diagnosis of pregnancy, is currently breastfeeding, or have a diagnosis of rhabdomyolysis?

- **No**
  - Patient who do **not** have documentation of either pregnancy, breastfeeding, or a diagnosis of rhabdomyolysis

- **Yes**
  - Patient with documentation of either pregnancy, breastfeeding, or a diagnosis of rhabdomyolysis
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

6. Was the patient taking or prescribed statin therapy during the measurement period (2017)?
   
   - Yes
     - Patient was taking or prescribed statin therapy

   - No
     - Patient was not taking or prescribed statin therapy

**Note:** Only statin therapy is included. Other cholesterol lowering medications alone are not included.
6. (Continued) Was the patient taking or prescribed statin therapy during the measurement period (2017)?

- No - Medical Reasons
  - documented adverse effect
  - allergy or intolerance
  - active diagnosis of pregnancy
  - currently breast feeding
  - receiving palliative care
  - active liver or hepatic disease or insufficiency
  - End Stage Renal Disease (ESRD)
  - OR most recent fasting or direct LDL-C lab test <70 mg/dL for diabetes diagnosis and currently not receiving statin medication therapy
### Approved Statins

<table>
<thead>
<tr>
<th>Generic</th>
<th>Brand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atorvastatin</td>
<td>Lipitor</td>
</tr>
<tr>
<td>Fluvastatin</td>
<td>Lescol XL or Lescol</td>
</tr>
<tr>
<td>Lovastatin (Mevinolin)</td>
<td>Mevacor or Altoprev</td>
</tr>
<tr>
<td>Pitavastatin</td>
<td>Livalo</td>
</tr>
<tr>
<td>Pravastatin Sodium</td>
<td>Pravachol</td>
</tr>
<tr>
<td>Rosuvastatin Calcium</td>
<td>Crestor</td>
</tr>
<tr>
<td>Simvastatin</td>
<td>Zocor</td>
</tr>
<tr>
<td>Amlodipine Besylate/Atorvastatin Calcuim</td>
<td>Caduet</td>
</tr>
<tr>
<td>Ezetimibe/Simvastatin</td>
<td>Vytorin</td>
</tr>
<tr>
<td>Niacin/Lovastatin</td>
<td>Advicor</td>
</tr>
<tr>
<td>Niacin/Simvastatin</td>
<td>Simcor</td>
</tr>
<tr>
<td>Sitagliptin/Simvastatin</td>
<td>Juvisync</td>
</tr>
<tr>
<td>Sitagliptin Phosphate/Simvastatin</td>
<td>Juntadueto</td>
</tr>
<tr>
<td>Atorvastatin/Ezetimibe</td>
<td>Liptruzet</td>
</tr>
<tr>
<td>Fenofibrate/Simvastatin</td>
<td>Cholib</td>
</tr>
</tbody>
</table>
Measure 42: Statin Therapy for Prevention and Treatment of Cardiovascular Disease

The following cholesterol medications are **NOT** statins and **do not meet the measure requirements:**

- Zetia
- Lopid
- Tricor
- Triglide
- Antara
- Lofibra
- Atromid-S
- Niacin
- Questran
- Colestid
- WelChol
Measure 42: Quick Tips

• Age Parameters:
  – Risk Category 1: Age 21 years and older
  – Risk Category 2: Age 21 years and older
  – Risk Category 3: Age 40-75 years

• Clinical Atherosclerotic Cardiovascular Disease (ASCVD) is defined as:
  Acute Coronary Syndromes, History of Myocardial Infarction, Stable or
  Unstable Angina, Coronary or other Arterial Revascularization, Stroke or
  Trans Ischemic Attack (TIA), Peripheral Artery Disease (PAD) of
  atherosclerotic origin

• Only statin therapy is included. Other cholesterol lowering medications (non-
  statins) alone are not included.

• Acceptable exceptions: documented adverse effect, allergy, or intolerance,
  currently pregnant or actively breastfeeding, receiving palliative care, active
  liver or hepatic disease or insufficiency, ESRD, OR most recent fasting or
direct LDL-C lab test <70 mg/dL for diabetes dx currently not receiving statin
  medications.
Measure 42: Skip Vs Performance Met

• **Beneficiary Skip**
  – Not Qualified = Hospice, Death, Moved Out of Country, Medicare Not Primary

• **Measure Skip**
  – No – Diagnosis
  – Q#4 response : No
    ✓ Patient does not have an LDL-C 70-189 mg/dL documented
    (If selected – Stop Abstraction for this measure)
  – Denominator Exclusion
    ✓ Patients who have a diagnosis of pregnancy
    ✓ Patients who are breastfeeding
    ✓ Patients who have a diagnosis of rhabdomyolysis
Measure 42: Skip Vs Performance Met

- **Removed from Performance Calculations**
  - Denominator Exceptions – Patients with:
    - adverse effect, allergy, or intolerance to statin medication
    - active liver disease or hepatic disease or insufficiency
    - end-stage renal disease (ESRD)
    - diabetes who have the most recent fasting or direct LDL-C laboratory test result < 70 mg/dL and are not taking statin therapy

- **Performance Met**
  - Patients who are statin therapy users during the measurement period or who receive an order (prescription) to receive statin therapy at any point during the measurement period

- **Performance Not Met**
  - Patients who are **not** statin therapy users during the measurement period
• **Inclusion in the Denominator:**
  – Beneficiary is qualified for the sample
  – Medical record is available
  – Age, diagnosis and timeframe qualifications met (see pages 3 and 5 -10)
  – Beneficiary is qualified for the measure (see page 4)
  – Not excluded per measure exceptions (see page 9)

• **Inclusion in the Numerator:**
  – Patients who are statin therapy users during the measurement period or who receive an order (prescription) to receive statin therapy at any point during the measurement period
Disclaimer:

This presentation was current at the time it was published. The CMS Programs are subject to policy changes. Links to the resource documents have been provided in the following page(s) within this document for your reference. Review the link(s) for specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.
Resources

• CMS Quality Payment Program website: https://qpp.cms.gov/resources/education

Educational Resources:
• Quality Measure Specifications: https://qpp.cms.gov/docs/QPP_quality_measure_specifications.zip